On February 13, 2023 Veracyte, Inc. (Nasdaq: VCYT) reported new data being presented this week at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary (ASCO GU) Symposium which demonstrate that a gene expression signature derived from the company’s proprietary Decipher Genomics Resource for Intelligent Discovery (GRID) database may help physicians further personalize treatment for men with prostate cancer, based on their tumor’s molecular subtype. Additional data being presented at the meeting, taking place in San Francisco and online, February 16-18, reinforce the clinical utility of the company’s Decipher Prostate Genomic Classifier.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In the first study (Abstract #241; Poster #J6), researchers analyzed data from Veracyte’s Decipher GRID database and found that classifying prostate cancer tumors by their molecular subtype could potentially inform their response to treatment. The researchers evaluated 1,015 men with either localized or metastatic hormone-sensitive prostate cancer (mHSPC) using a Decipher GRID-derived, 215-gene expression signature that was previously shown to classify prostate cancer into four molecular subtypes: luminal differentiated, luminal proliferating, basal immune, and basal neuroendocrine-like.
The findings demonstrated that, after radical prostatectomy, men with luminal differentiated tumors had the most favorable prognosis and those with basal immune tumors derived the greatest metastasis-free survival benefit from postoperative radiotherapy, while those with other subtypes did not see the same benefit. Additionally, in men with metastatic disease, those with luminal proliferating tumors derived the greatest survival benefit from the addition of docetaxel to androgen deprivation therapy.
"These findings demonstrate that our Decipher GRID database can provide researchers with new insights that may help physicians further apply a precision medicine approach to treatment of their prostate cancer patients," said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. "This and the multiple, additional Decipher-focused abstracts being presented at ASCO (Free ASCO Whitepaper) GU reinforce our commitment to research that aims to help physicians provide their patients with the best care possible and advance our collective understanding of the molecular underpinnings of prostate cancer."
The Decipher GRID database includes more than 100,000 whole-transcriptome profiles from patients with urologic cancers and is used by Veracyte and its research partners to help advance understanding of prostate and other urologic cancers. GRID-derived information is available on a Research Use Only basis to physicians who have ordered the Decipher Prostate Genomic Classifier.
In another study to be shared at ASCO (Free ASCO Whitepaper) GU (Abstract #345; Poster #M3), researchers evaluated the impact of the Decipher Prostate Genomic Classifier on patient-reported, quality-of-life outcomes. Previously presented data from the same trial show that men who received Decipher Prostate testing were more likely to receive adjuvant radiation therapy following radical prostatectomy than men who did not undergo genomic testing. The new analysis shows that, despite receiving more adjuvant radiation therapy, the men who underwent Decipher Prostate testing experienced no significant difference in quality-of-life reported outcomes related to urinary or sexual function as compared to their untested peers. These findings are from the G-MINOR trial, the first, prospective, randomized trial to evaluate the clinical utility of any prostate cancer genomic classifier. The trial enrolled 356 patients from 12 centers through the Michigan Urological Surgery Improvement Collaborative (MUSIC).
"These new findings suggest that there is no adverse quality-of-life impact for men whose tumors undergo Decipher Prostate testing compared to those whose do not," said Udit Singhal, M.D., a urologist at University of Michigan Health. "This finding should give physicians even more confidence in using the Decipher Prostate test to help inform treatment decisions for their patients with prostate cancer."
The Decipher Prostate Genomic Classifier is a 22-gene prognostic biomarker that provides a low, intermediate or high score indicating the aggressiveness of an individual patient’s cancer, to help healthcare professionals more accurately categorize risk and select appropriate treatment.